Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Naveed K Shams"'
Autor:
Hisashi Kawata, Makoto Aihara, Noriko Odani-Kawabata, Fenghe Lu, Akihiro Iwata, Naveed K Shams
Publikováno v:
American Journal of Ophthalmology. 220:53-63
Purpose To evaluate the efficacy and safety of omidenepag isopropyl (OMDI), a selective, non-prostaglandin, prostanoid EP2 receptor agonist, in Japanese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Design Phase III,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::615c1c847eac80b5c72a17ffb92ab991
https://doi.org/10.1016/j.ajo.2020.06.003
https://doi.org/10.1016/j.ajo.2020.06.003
Autor:
Yasuko Yamamoto, Naveed K Shams, Tomoaki Inazumi, Yukihiko Sugimoto, Takazumi Taniguchi, Ryo Iwamura, Kenji Yoneda, Takeshi Matsugi, Noriko Odani-Kawabata
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics
Purpose: We aimed at comparing the effects of omidenepag (OMD) with those of prostaglandin F (FP) receptor agonists (FP agonists) on adipogenesis in mouse 3T3-L1 cells. Methods: To evaluate the agonistic activities of OMD against the mouse EP2 (mEP2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0840fb5ebe9992ea1bb8a9a4fc14fb
http://europepmc.org/articles/PMC7175626
http://europepmc.org/articles/PMC7175626
Autor:
Fenghe Lu, Makoto Aihara, Kenzo Yamamura, Noriko Odani-Kawabata, Yuki Tanaka, Naveed K Shams, Hisashi Kawata
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics
Purpose: Omidenepag isopropyl (OMDI) is a prodrug of OMD, a selective, nonprostaglandin, prostanoid EP2 receptor agonist. This phase I study aimed to investigate the pharmacokinetic properties, safety, and intraocular pressure (IOP)-lowering efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1570f9357ec6e5e22a9c48f986cc2745
http://europepmc.org/articles/PMC6918846
http://europepmc.org/articles/PMC6918846
Autor:
Noriko Odani-Kawabata, Michelle Sato, Phillip Dinh, Marc A Abrams, Fenghe Lu, Kenneth Olander, Almira Chabi, Gary Jerkins, Naveed K Shams
Publikováno v:
Journal of Glaucoma
Prcis No significant difference was found between the intraocular pressure (IOP) lowering of omidenepag isopropyl 0.002% once daily (QD) and twice daily (BID). However, adverse events (AEs) were higher in the BID arm; thus, QD dosing is the preferred
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2fd8b013e3f4733e4d132b49834a4a
https://pubmed.ncbi.nlm.nih.gov/33813559
https://pubmed.ncbi.nlm.nih.gov/33813559
Autor:
Kenji Yoneda, Shan Fan, Carol B. Toris, Masaki Ichikawa, Masahiro Fuwa, Ryo Iwamura, Jin-Zhong Zhang, Takeshi Matsugi, Naveed K Shams, Noriko Odani-Kawabata, Takazumi Taniguchi
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 34:531-537
To investigate the mechanism of the intraocular pressure (IOP)-lowering effect of a novel selective prostaglandin E2 receptor 2 (EP2) receptor agonist, omidenepag isopropyl (OMDI).The effect of OMDI on IOP and aqueous humor dynamics was evaluated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7af79a7095b0c5229d6e5c385c6c4147
https://doi.org/10.1089/jop.2017.0146
https://doi.org/10.1089/jop.2017.0146
Autor:
Makoto, Aihara, Fenghe, Lu, Hisashi, Kawata, Akihiro, Iwata, Noriko, Odani-Kawabata, Naveed K, Shams
Publikováno v:
American journal of ophthalmology. 220
To evaluate the efficacy and safety of omidenepag isopropyl (OMDI), a selective, non-prostaglandin, prostanoid EP2 receptor agonist, in Japanese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).Phase III, randomized, inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0cc9527817e02b140f6b5f5efb65a4e7
https://pubmed.ncbi.nlm.nih.gov/34462073
https://pubmed.ncbi.nlm.nih.gov/34462073
Autor:
Akihiro Iwata, Hisashi Kawata, Auli Ropo, Fenghe Lu, Makoto Aihara, Noriko Odani-Kawabata, Naveed K Shams
Publikováno v:
Japanese journal of ophthalmology. 64(4)
Omidenepag isopropyl (OMDI) is the prodrug of omidenepag, a selective, non-prostaglandin, prostanoid EP2 receptor agonist, which has been shown to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension (OHT). This study ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51fd1e4bc08bd44908d4f6dfeb2178e7
https://pubmed.ncbi.nlm.nih.gov/32572719
https://pubmed.ncbi.nlm.nih.gov/32572719
Autor:
Noriko Odani-Kawabata, Makoto Aihara, Fenghe Lu, Akihiro Iwata, Hisashi Kawata, Naveed K Shams, Kathy Liu
Publikováno v:
Journal of glaucoma. 28(5)
PRéCIS:: Three randomized, multicenter studies demonstrated the stable intraocular pressure-lowering effects and tolerability of omidenepag isopropyl in patients with primary open-angle glaucoma and ocular hypertension; 0.002% was identified as the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd6bd73996a82d7a3bf3eec23c32d3f4
https://pubmed.ncbi.nlm.nih.gov/30839416
https://pubmed.ncbi.nlm.nih.gov/30839416
Autor:
Eiji Okanari, Tomoko Kirihara, Kenji Yoneda, Ryo Iwamura, Naveed K Shams, Noriko Odani-Kawabata, Masayuki Tanaka
Publikováno v:
Journal of medicinal chemistry. 61(15)
EP2 receptor agonists are expected to be effective ocular hypotensive agents; however, it has been suggested that agonism to other EP receptor subtypes may lead to undesirable effects. Through medicinal chemistry efforts, we identified a scaffold bea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f458e261a47f1077ac8e3431a66d45
https://pubmed.ncbi.nlm.nih.gov/29995405
https://pubmed.ncbi.nlm.nih.gov/29995405
Autor:
Takazumi Taniguchi, Noriko Odani-Kawabata, Tomoko Kirihara, Atsushi Shimazaki, Kenzo Yamamura, Kenji Yoneda, Takeshi Matsugi, Jin-Zhong Zhang, Naveed K Shams, Ryo Iwamura
Publikováno v:
Investigative Opthalmology & Visual Science. 59:145
Purpose The objective of this study was to investigate the pharmacologic characteristics of omidenepag isopropyl (OMDI), a compound developed as a novel intraocular pressure (IOP)-lowering agent, with better IOP control and fewer side effects than ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b73ea39ab3a1504a8f4aeb4389c141
https://doi.org/10.1167/iovs.17-22745
https://doi.org/10.1167/iovs.17-22745